SC
SMMT icon

Sculptor Capital’s Summit Therapeutics SMMT Stock Holding History

Sculptor Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-356,900
Closed -$6.24M – 433
2025
Q4 		$6.24M Buy
356,900
+23,400
+7% +$440K 0.06% 173
2025
Q3 		$6.89M Buy
+333,500
New +$8.09M 0.08% 166

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sculptor Capital's SMMT Position: Q1 2026 in Review

Sculptor Capital sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 356,900 shares — an estimated $6.24M sold.

Sculptor Capital first reported a position in SMMT in Q3 2025 and held it in 2 quarters. The position peaked at $6.89M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Sculptor Capital reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sculptor Capital sold 356,900 Summit Therapeutics shares in Q1 2026, an estimated $6.24M.
  • Sculptor Capital first reported a position in Summit Therapeutics in Q3 2025 and held it in 2 quarters.
  • Sculptor Capital's Summit Therapeutics position peaked at $6.89M in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.